1 / 69

Impact of New Anticoagulants on the Blood Bank

Impact of New Anticoagulants on the Blood Bank. January 24 th , 2012 Transfusion Medicine Resident Teaching Session Dr. Sudeep Shivakumar, Hematology. Objectives. To briefly review the concepts of hemostasis and thrombosis To provide an overview of anticoagulants currently in use

verne
Download Presentation

Impact of New Anticoagulants on the Blood Bank

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Impact of New Anticoagulants on the Blood Bank January 24th, 2012 Transfusion Medicine Resident Teaching Session Dr. Sudeep Shivakumar, Hematology

  2. Objectives • To briefly review the concepts of hemostasis and thrombosis • To provide an overview of anticoagulants currently in use • To discuss the new anticoagulant agents and their mechanism of action • To review the evidence for the new anticoagulants in DVT/PE and atrial fibrillation • To discuss implications of these medications for the blood bank

  3. Overview • Anticoagulants are widely used • Vitamin K antagonists used to be the only oral option • Times are changing…

  4. Overview • Big advantage: • No lab monitoring • Big disadvantage: • No lab monitoring • Unpredictability of coagulation tests • No reversal agents • Variety of different agents with different characteristics

  5. Background • What are anticoagulants? • Substances that prevent blood from clotting • “Blood thinners” • How do they do this? • Interfering with coagulation mechanisms

  6. Hemostasis • Complex process which causes bleeding to stop: • Formation of blood clot formation at the site of vessel injury • Carefully regulated system • Involves platelets and coagulation factors • Lack of coagulation factors  bleeding • Overactive coagulation cascade  thrombosis

  7. Thrombosis • The formation of a blood clot within a blood vessel • Can occur in the arterial or venous systems • Leads to obstruction of a blood vessel in the circulatory system • Can lead to ischemia and infarction, and even death • Can also lead to embolism • Clot within a vessel breaks free and travels through body (“embolizes”) • Thromboembolism is combination of a thrombosis and embolus

  8. Atrial fibrillation • Most common cardiac rhythm disorder • Affects >10% in those > 80 years old Incidence of atrial fibrillation in 4000 male air crew recruits Krahn et al, Am J Med, 1995

  9. Atrial fibrillation • Lifetime risk for a 40 year old is ~25% (Framingham1) • Independent risk factor for ischemic stroke • Rate of stroke in those not on antithrombotic therapy is ~4.5%/year • Increases the risk of stroke 5x across all age groups • Incidence of stroke increases with age2 • 1.3% per year for those aged 50-59 • 5.1% per year for those aged 80-89 1Wolf, Stroke, 1991 2Frost, Am J Med, 2000

  10. Anticoagulants in atrial fibrillation • Goal is to prevent stroke • Reduces risk to ~1% per year • Warfarin shown to be more effective than aspirin

  11. Warfarin in atrial fibrillation Warfarin Better Control Better AFASAK SPAF BAATAF CAFA SPINAF EAFT Aggregate -100% 50% -50% 100% 0 Hart R, et al. Ann Intern Med 1999;131:492

  12. Anticoagulants in atrial fibrillation • Most recent Canadian Cardiovascular Society guidelines (2010): • Patients with CHADS2 score of 1 or higher should be on oral anticoagulants

  13. Venous thromboembolism Deep venous thrombosis Pulmonary embolism

  14. Venous thromboembolism • Venous stasis Hypercoagulability Vessel wall injury Incidence estimated at 1-2 in 1000 Known predisposing conditions – Virchow’s triad:

  15. Venous thromboembolism • Not uncommon • Longitudinal investigation of thromboembolism etiology (LITE) study1 • >21 000 participants • Cohort study • Incidence of 1st time VTE = 1.92 per 1000 person years • Major cause of morbidity and mortality • JAMA study2 looking at post-mortems of 3 412 hospitalized patients between 1966 and 1980 • 6% of deceased patients had evidence of massive pulmonary embolism • Most common preventable cause of in-hospital death 1Cushman, Am J Med, 2004 2Dismuke, JAMA, 1986

  16. Pulmonary embolism • Untreated PE • Mortality rate of ~30%1 • Most die within hours of diagnosis • Treated PE • Prospective NEJM study looked at 399 patients with newly diagnosed PE • 94% received anticoagulant treatment • Only 2.5% (10 patients) died of PE • Treatment of PE is life-saving! 1Dalen, Prog Cardiovasc Dis, 1975 2Carson,NEJM, 1992

  17. Anticoagulants in DVT/PE • Goals of treatment: • Short term: • Prevent the extension of thrombus and embolization for DVT • Reduce mortality for PE by reducing recurrent events • Relief of symptoms • Long term: • Prevent recurrent events

  18. Anticoagulants currently used • Unfractionated heparin • Low molecular weight heparin • Vitamin K antagonists • Ie. warfarin

  19. Warfarin • Can be reversed: • Vitamin K • Fresh frozen plasma • Activated prothrombin complex concentrates

  20. Warfarin • Dosage varies because of: • Vitamin K status • Dietary factors • Nausea/vomiting • Absorption • Activity level • Other medications • Genetics • Monitoring by INR necessary!

  21. Difficulties with warfarin use • Requires monitoring • Numerous drug and diet interactions • Narrow therapeutic range • Difficult to control – takes time to get in or out of the system Role for new anticoagulants?

  22. New anticoagulants • Many new targets being explored • Eg. thrombin, factor Xa, tissue factor, protein C, factor V and VIII • New agents developed • Direct thrombin inhibitors • Factor Xa inhibitors • Novel anticoagulants • Oral agents increasingly in studies • Venous thromboembolism often studied first because of shorter follow up • Increasing data on dabigatran and rivaroxaban

  23. New anticoagulants • Ideal anticoagulant: • Equally efficacious • Equally safe • No monitoring • Fewer interactions • Oral • Reversible

  24. New anticoagulants • Direct thrombin inhibitors • Dabigatran • Factor Xa inhibitors • Rivaroxaban

  25. New anticoagulants Leung, The Hematologist, 2011

  26. Dabigatran • Ximelagatran studies showed possible use for oral direct thrombin inhibitors in atrial fibrillation • Dabigatran • Oral prodrug of dabigatran etixalate • Inhibitor of thrombin • Predictable anticoagulant response • No need for monitoring • Excreted by kidneys • Less than 1% see a transaminase elevation

  27. Dabigatran • An ideal anticoagulant: • No monitoring • Fewer interactions • Oral • Reversible • Equally efficacious • Equally safe

  28. Dabigatran ✓ ✓ ✓ ✗ ? ? • An ideal anticoagulant: • No monitoring • Fewer interactions • Oral • Reversible • Equally efficacious • Equally safe

  29. Dabigatran • Pharmacokinetics • Half life 12-17 hours • Time to peak, plasma 1 hour • Hepatic metabolism • Not recommended for CrCl <30

  30. Dabigatran • Many studies for VTE prophylaxis: • REMODEL – thromboprophylaxis after knee surgery • REMOBILIZE – thromboprohylaxis after knee surgery • RENOVATE I and II – thromboprophylaxis after hip surgery • Studies for VTE treatment: • RECOVER – acute VTE treatment • REMEDY – secondary VTE prevention • Studies for atrial fibrillation: • PETRO study – phase II • RELY study – phase III

  31. Dabigatran for atrial fibrillation • RELY trial • Looked at stroke prevention in patients with atrial fibrillation • Compared warfarin to dabigatran • >18 000 patients • Results: • 110 mg BID dose of dabigatran as effective and less bleeding • 150 mg BID dose more effective, similar bleeding • Published in NEJM in September 2009 (Connolly et al)

  32. Dabigatran for atrial fibrillation • RELY trial • Note trend towards increased MI rates with dabigatran 150 mg BID • Also increased dyspepsia • Consider higher dose if <80 and low risk of bleeding

  33. Dabigatran for VTE • RECOVER trial • Dabigatran exilate vs warfarin in the treatment of acute thromboembolism • Randomized double blind trial • 2539 patients with acute VTE • All treated initially with 5 to 11 days of LMWH or UFH • Randomized to dabigatran 150 mg BID vs warfarin • Primary outcome: objective recurrent VTE, or VTE-related death up to 6 months of treatment

  34. Dabigatran for VTE • RECOVER trial • Results: • Recurrent VTE: • 34 patients (2.7%) in dabigatran group • 32 patients (2.5%) in warfarin group (not significant) • Major bleeding: • 20 patients (1.6%) in dabigatran group • 24 patients (1.9%) in warfarin group (significant) • Deaths similar between groups • Conclusions: • Dabigatran as safe and efficacious as warfarin • Published in NEJM in December 2009 (Schulman et al)

  35. Dabigatran • Approved by Health Canada for atrial fibrillation • Not covered by MSI… yet • Not approved for VTE treatment • Costs $2.30 per day

  36. Dabigatran and coagulation assays

  37. Dabigatran and coagulation assays • aPTT affected at peak concentrations • aPTT >90 sec suggests over-dosing or accumulation • PT not affected • Fibrinogen testing underestimated results in 2 of 4 reagents • Antithrombin levels varied greatly • Overall, unpredictable results, but elevated aPTT suggested accumulation

  38. Factor Xa inhibitors • Lack of direct thrombin inhibition = less bleeding?

  39. Rivaroxaban • Oral, direct factor Xa inhibitor • Potent (greater selectivity for factor Xa than other drugs) • Fixed, once-daily dosing • Predictable pharmacokinetics • Half life 7-11 hours • Peak concentration 4hrs after administration • Excreted via biliary and renal routes • Does have interactions CYP3A4 inhibitors • Ie. ketoconazole, macrolides

More Related